
Opinion|Videos|January 29, 2025
Monitoring Patients Transitioning From Obeticholic Acid
Panelists discuss how transitioning patients from obeticholic acid to seladelpar or elafibranor requires close monitoring of liver biochemistry, pruritus severity, medication adverse effects, and quality of life measures while providing clear patient education about expected timeline for symptom improvement and potential adjustment periods.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What key monitoring parameters should be prioritized when transitioning a patient from obeticholic acid to either seladelpar or elafibranor, especially during the initial stages of therapy?
- How should clinicians counsel patients on the expected changes in symptom management and potential side effects when transitioning from obeticholic acid to another PBC therapy?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
How Pharmacists Can Close the Opioid Addiction Care Gap
2
Once-Weekly Retatrutide Reduces Weight and Knee Pain in Patients With Obesity and Osteoarthritis
3
FDA Approval Signals Broader Recognition of Sexual Health in Aging Women
4
FDA Approves T-DXd With Pertuzumab for First-Line Treatment of Advanced HER2+ Breast Cancer
5















































































































































































































